oxybutynin has been researched along with Neuralgia in 45 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of chronic pain conditions is commonly assessed at specific endpoints at preset times during or after treatment by analysis of the total study population." | 6.78 | A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. ( Dahan, A; Krebs-Brown, A; Martini, CH; Olofsen, E; Passier, P; Stoker, M; Yassen, A, 2013) |
| "Neuropathic pain is defined as a direct consequence of an injury or disease that affects the somatosensory system, which may affect 7 to 10% of the world population." | 5.56 | Peripheral Neuropathy Associated with Hypereosinophilic Syndrome: A Clinical Therapeutic Success with Capsaicin 8% Patch. ( Gestosa, SVS; Lares, AMG; Mulenas, NME; Ruivo, EFM, 2020) |
| "Twenty patients with ESRD were treated with Qutenza® for neuropathic pain from critical limb ischemia." | 5.46 | The Role of Qutenza® (Topical Capsaicin 8%) in Treating Neuropathic Pain from Critical Ischemia in Patients with End-Stage Renal Disease: An Observational Cohort Study. ( Aitken, E; Kingsmore, D; McColl, G, 2017) |
| "A number of studies have been published proposing various approaches to the treatment of neuropathic pain; however, to our knowledge, no attempts have been made to compare gabapentin and fentanyl in patients with lumbar radiculopathy." | 5.30 | Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial. ( Hwang, CJ; Kim, JH; Lee, JH; Min, SH; Park, KW; Seo, HY; Song, KS, 2019) |
| "A prospective, open-label, observational study in patients with postherpetic neuralgia, posttraumatic or postsurgical nerve injury, HIV-associated distal sensory polyneuropathy, or other peripheral neuropathic pain, and average daily pain score ≥4, who received ≤6 capsaicin 8% patch treatments over 52 weeks according to clinical need (retreatment at 9 to 12 wk intervals)." | 5.24 | Capsaicin 8% Patch Repeat Treatment in Nondiabetic Peripheral Neuropathic Pain: A 52-Week, Open-Label, Single-Arm, Safety Study. ( Attal, N; Ernault, E; Gálvez, R; Maihöfner, C; Moyle, G; Navez, ML; Nurmikko, TJ; Stoker, M, 2017) |
| " A high-concentration capsaicin 179-mg cutaneous patch (Qutenza™) is licensed in adults for chronic neuropathic pain in the EU, and neuropathic pain with post-herpetic neuralgia and neuropathic pain with diabetic peripheral neuropathy in the USA." | 5.12 | Capsaicin 179-mg cutaneous patch in the treatment of post-surgical neuropathic pain: a scoping review of current evidence and place in therapy. ( Casale, R, 2021) |
| "Clinical trials have found 5% lidocaine patches to be effective and well tolerated for the treatment of post-herpetic neuralgia (PHN) with a minimal risk of toxicity or drug-drug interactions." | 5.05 | Utility of lidocaine as a topical analgesic and improvements in patch delivery systems. ( Gudin, J; Nalamachu, S, 2020) |
| "Qutenza® is a capsaicin patch used to treat peripheral neuropathic pain, including postherpetic neuralgia (PHN) and human immunodeficiency virus-associated neuropathy (HIV-AN)." | 4.89 | Efficacy of Qutenza® (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database. ( Katz, NP; Mou, J; Paillard, F; Stoker, M; Trudeau, J; Turnbull, B, 2013) |
| " Lidocaine patches reduce neuropathic pain in postherpetic neuralgia, but their benefits for cancer-related neuropathic pain remain unclear." | 4.31 | Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment. ( Chen, YY; Chiu, GL; Huang, YT; Lai, WS; Lin, PC; Liu, IT; Su, PF; Tsai, JH, 2023) |
| " The capsaicin 8% patch is a Food and Drug Administration-approved treatment of neuropathic pain in postherpetic neuralgia and has demonstrated significant efficacy in human immunodeficiency virus-autonomic neuropathy." | 3.81 | Capsaicin 8% Patch for Central and Peripheral Neuropathic Pain of Persons with Incomplete Spinal Cord Injury: Two Case Reports. ( Trbovich, M; Yang, H, 2015) |
| "Overall, 68 patients with PNP conditions, including facial neuropathy (severe trigeminal neuralgia in V2), polyneuropathy, post-herpetic neuralgia, and mononeuropathies, received 96 treatments with the capsaicin 8% patch." | 3.79 | The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis. ( Poole, C; Roth-Daniek, A; Wagner, T, 2013) |
| " For the safety evaluation, 2 severe adverse events were reported for the 0." | 2.84 | Efficacy and Safety of 0.625% and 1.25% Capsaicin Patch in Peripheral Neuropathic Pain: Multi-Center, Randomized, and Semi-Double Blind Controlled Study. ( Choi, E; Kim, YC; Lee, PB; Lee, SC; Moon, JY; Nahm, FS, 2017) |
| "Analgesic treatment of peripheral neuropathic pain with the capsaicin 8% cutaneous patch is safe and effective." | 2.78 | Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. ( Heskamp, ML; Maihofner, C, 2013) |
| "Treatment of chronic pain conditions is commonly assessed at specific endpoints at preset times during or after treatment by analysis of the total study population." | 2.78 | A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. ( Dahan, A; Krebs-Brown, A; Martini, CH; Olofsen, E; Passier, P; Stoker, M; Yassen, A, 2013) |
| "Localized neuropathic pain (LNP) is a type of neuropathic pain characterized by consistent and circumscribed area(s) of maximum pain, which are associated with negative or positive sensory signs and/or spontaneous symptoms typical of neuropathic pain." | 2.50 | [Localized neuropathic pain--5% lidocaine medicated patch as a first-line treatment and as add-on therapy: literature review and personal experience]. ( Bhaskar, A; Casale, R; Coluzzi, F; Consalvo, M; Polati, E; Schweiger, V, 2014) |
| "Diagnosis of neuropathic pain was based on the Douleur Neuropathique 4 (DN4) questionnaire." | 1.72 | Capsaicin 8% Dermal Patch for Neuropathic Pain in a Pain Unit. ( Ausín-Crespo, MD; de la Beldad-Diez, ML; Martín-de Castro, E; Roldán-Cuartero, J; Salcedo-Gámez, MÁ; Tong, H, 2022) |
| "Chronic neuropathic pain is a disabling condition that affects quality of life." | 1.72 | Capsaicin 8% for Peripheral Neuropathic Pain Treatment: A Retrospective Cohort Study. ( Assuncao, JP; Cardoso, C; de Castro, AM; Loureiro, MDC; Pinto, J; Vieira, IF, 2022) |
| "Gabapentin (GBP) is an FDA-approved drug for the treatment of partial and secondary generalized seizures, apart from being used for diabetic neuropathic pain." | 1.62 | In-Silico Validation and Fabrication of Matrix Diffusion-Based Polymeric Transdermal Patches for Repurposing Gabapentin Hydrochloride in Neuropathic Pain. ( Agarwal, S; Agarwal, V; Kaur, H; Kaur, R; Pancham, P; Singh, M, 2021) |
| "We report a case of chronic left flank neuropathic pain after a renal cyst removal in a 54-year old female." | 1.62 | Post Laparoscopy Neuropathic Pain Treated by Capsaicin 8% Dermal Patch. ( Economou, S; Samara, E; Stamatiou, K; Tzimas, P, 2021) |
| "Although some patients with peripheral neuropathic pain experience rapid improvements with a single treatment of capsaicin 179 mg patch, some may require two or three treatments before an initial response is observed." | 1.62 | Progressive Response to Repeat Application of Capsaicin 179 mg (8% w/w) Cutaneous Patch in Peripheral Neuropathic Pain: Comprehensive New Analysis and Clinical Implications. ( Argoff, C; Eerdekens, M; Engelen, S; Freynhagen, R; Perrot, S, 2021) |
| "Neuropathic pain is defined as a direct consequence of an injury or disease that affects the somatosensory system, which may affect 7 to 10% of the world population." | 1.56 | Peripheral Neuropathy Associated with Hypereosinophilic Syndrome: A Clinical Therapeutic Success with Capsaicin 8% Patch. ( Gestosa, SVS; Lares, AMG; Mulenas, NME; Ruivo, EFM, 2020) |
| "Neuropathic pain is a complex condition that is difficult to control and has a high impact on quality of life." | 1.56 | 8% Capsaicin Patch in Treatment of Peripheral Neuropathic Pain. ( Barbosa, P; Gomes, A; Goncalves, D; Rebelo, V, 2020) |
| "Several guidelines for neuropathic pain management and various effective drugs are available; however, neuropathic pain remains undertreated." | 1.48 | Efficacy Analysis of Capsaicin 8% Patch in Neuropathic Peripheral Pain Treatment. ( Fernandes, HL; Gama, R; Loureiro, MC; Pereira, FC; Tenreiro Pinto, J, 2018) |
| "Localized neuropathic pain (LNP) is a subgroup of neuropathic pain characterized by consistent and circumscribed area(s) of maximum pain, associated with negative or positive sensory signs and/or spontaneous symptoms characteristic of NP." | 1.48 | Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy. ( Chinellato, E; Del Balzo, G; Martini, A; Parolini, M; Picelli, A; Polati, E; Schweiger, V; Tamburin, S; Zanzotti, M, 2018) |
| "Twenty patients with ESRD were treated with Qutenza® for neuropathic pain from critical limb ischemia." | 1.46 | The Role of Qutenza® (Topical Capsaicin 8%) in Treating Neuropathic Pain from Critical Ischemia in Patients with End-Stage Renal Disease: An Observational Cohort Study. ( Aitken, E; Kingsmore, D; McColl, G, 2017) |
| "We are reporting on four patients with neuropathic pain syndromes successfully treated with a capsaicin 8% patch in the affected area of the head or face." | 1.42 | Application of the capsaicin 8% cutaneous patch in neuropathic pain of the head and face: A case series. ( Gaul, C; Resch, S, 2015) |
| "Lidocaine pretreatment does not have a significant effect on tolerability, efficacy, or patient willingness to receive retreatment." | 1.40 | Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary? ( Kern, KU; Nowack, W; Poole, C, 2014) |
| "Both buprenorphine and fentanyl were well tolerated." | 1.39 | Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients. ( Cannata, F; Canneti, A; Di Marco, P; Luzi, M; Pasqualitto, F; Reale, C; Spinoglio, A, 2013) |
| "This syndrome is usually related to anatomic variants (involving the bone structures, fibrous bands, or muscles and tendons)." | 1.38 | Supraclavicular nerve entrapment syndrome. ( Bruyère, PJ; Courtois, AC; Crielaard, JM; Douchamps, F, 2012) |
| "Additionally, gabapentin was given for neuropathic pain uncontrolled by opioids." | 1.37 | [Oxycodone and pregabalin using transdermal fentanyl patch provided relief of symptoms for postherpetic neuropathic pain in a patient with non-small cell lung cancer]. ( Ando, A; Nishimura, D; Shibahara, H; Suzuki, S; Uematsu, N, 2011) |
| "A patient with C6D tetraplegia who sustained intoxication because of drug interaction is presented." | 1.33 | Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report. ( Bluvstein, V; Catz, A; Odi, H; Ronen, J; Vander, T, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.22) | 29.6817 |
| 2010's | 32 (71.11) | 24.3611 |
| 2020's | 12 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Vander, T | 1 |
| Odi, H | 1 |
| Bluvstein, V | 1 |
| Ronen, J | 1 |
| Catz, A | 1 |
| Casale, R | 2 |
| Ausín-Crespo, MD | 1 |
| Martín-de Castro, E | 1 |
| Roldán-Cuartero, J | 1 |
| de la Beldad-Diez, ML | 1 |
| Salcedo-Gámez, MÁ | 1 |
| Tong, H | 1 |
| Vieira, IF | 1 |
| de Castro, AM | 1 |
| Loureiro, MDC | 1 |
| Pinto, J | 1 |
| Cardoso, C | 1 |
| Assuncao, JP | 1 |
| Tsai, JH | 1 |
| Liu, IT | 1 |
| Su, PF | 1 |
| Huang, YT | 1 |
| Chiu, GL | 1 |
| Chen, YY | 1 |
| Lai, WS | 1 |
| Lin, PC | 1 |
| Gudin, J | 1 |
| Nalamachu, S | 1 |
| Cohrs, J | 1 |
| Kerns, R | 1 |
| Ruivo, EFM | 1 |
| Gestosa, SVS | 1 |
| Mulenas, NME | 1 |
| Lares, AMG | 1 |
| Bonezzi, C | 1 |
| Costantini, A | 1 |
| Cruccu, G | 2 |
| Fornasari, DMM | 1 |
| Guardamagna, V | 1 |
| Palmieri, V | 1 |
| Polati, E | 3 |
| Zini, P | 1 |
| Dickenson, AH | 1 |
| Goncalves, D | 1 |
| Rebelo, V | 1 |
| Barbosa, P | 1 |
| Gomes, A | 1 |
| Singh, M | 1 |
| Agarwal, S | 1 |
| Pancham, P | 1 |
| Agarwal, V | 1 |
| Kaur, H | 1 |
| Kaur, R | 1 |
| Samara, E | 1 |
| Stamatiou, K | 1 |
| Economou, S | 1 |
| Tzimas, P | 1 |
| Freynhagen, R | 2 |
| Argoff, C | 1 |
| Eerdekens, M | 1 |
| Engelen, S | 1 |
| Perrot, S | 2 |
| van Nooten, F | 1 |
| Treur, M | 1 |
| Pantiri, K | 1 |
| Stoker, M | 4 |
| Charokopou, M | 1 |
| Mankowski, C | 1 |
| Poole, CD | 1 |
| Ernault, E | 4 |
| Thomas, R | 1 |
| Berni, E | 1 |
| Currie, CJ | 1 |
| Treadwell, C | 1 |
| Calvo, JI | 1 |
| Plastira, C | 1 |
| Zafeiropoulou, E | 1 |
| Odeyemi, I | 1 |
| Filipczak-Bryniarska, I | 1 |
| Krzyzewski, RM | 1 |
| Kucharz, J | 1 |
| Michalowska-Kaczmarczyk, A | 1 |
| Kleja, J | 1 |
| Woron, J | 1 |
| Strzepek, K | 1 |
| Kazior, L | 1 |
| Wordliczek, J | 1 |
| Grodzicki, T | 1 |
| Krzemieniecki, K | 1 |
| Gálvez, R | 1 |
| Navez, ML | 1 |
| Moyle, G | 1 |
| Maihöfner, C | 2 |
| Nurmikko, TJ | 2 |
| Attal, N | 1 |
| Hansson, P | 1 |
| Jensen, TS | 2 |
| Kvarstein, G | 1 |
| Strömberg, M | 1 |
| Tenreiro Pinto, J | 1 |
| Pereira, FC | 1 |
| Loureiro, MC | 1 |
| Gama, R | 1 |
| Fernandes, HL | 1 |
| Martini, A | 1 |
| Del Balzo, G | 1 |
| Schweiger, V | 2 |
| Zanzotti, M | 1 |
| Picelli, A | 1 |
| Parolini, M | 1 |
| Chinellato, E | 1 |
| Tamburin, S | 1 |
| Blair, HA | 1 |
| Lantéri-Minet, M | 1 |
| Hwang, CJ | 1 |
| Lee, JH | 1 |
| Kim, JH | 1 |
| Min, SH | 1 |
| Park, KW | 1 |
| Seo, HY | 1 |
| Song, KS | 1 |
| Treede, RD | 1 |
| Wagner, T | 2 |
| Kern, KU | 2 |
| Husstedt, IW | 2 |
| Arendt, G | 1 |
| Birklein, F | 1 |
| Cegla, T | 1 |
| Gockel, HH | 1 |
| Heskamp, ML | 2 |
| Jager, H | 1 |
| Joppich, R | 1 |
| Maier, C | 1 |
| Leffler, A | 1 |
| Nagelein, HH | 1 |
| Rolke, R | 1 |
| Seddigh, S | 1 |
| Sommer, C | 1 |
| Stander, S | 1 |
| Wasner, G | 1 |
| Baron, R | 1 |
| Simpson, DM | 1 |
| Brown, S | 1 |
| Tobias, JK | 1 |
| Vanhove, GF | 1 |
| Canneti, A | 1 |
| Luzi, M | 1 |
| Di Marco, P | 1 |
| Cannata, F | 1 |
| Pasqualitto, F | 1 |
| Spinoglio, A | 1 |
| Reale, C | 1 |
| Martini, CH | 1 |
| Yassen, A | 1 |
| Krebs-Brown, A | 1 |
| Passier, P | 1 |
| Olofsen, E | 1 |
| Dahan, A | 1 |
| Mou, J | 1 |
| Paillard, F | 1 |
| Turnbull, B | 1 |
| Trudeau, J | 1 |
| Katz, NP | 1 |
| Poole, C | 2 |
| Roth-Daniek, A | 1 |
| Weekes, G | 1 |
| O'Brien, J | 1 |
| Murphy, K | 1 |
| Keavney, J | 1 |
| Pollard, V | 1 |
| Garzón-Rodríguez, C | 1 |
| Casals Merchan, M | 1 |
| Calsina-Berna, A | 1 |
| López-Rómboli, E | 1 |
| Porta-Sales, J | 1 |
| Nowack, W | 1 |
| Høye, K | 1 |
| Fricová, J | 1 |
| Vanelderen, P | 1 |
| Siciliano, T | 1 |
| Marques, S | 1 |
| Coluzzi, F | 1 |
| Bhaskar, A | 1 |
| Consalvo, M | 1 |
| Gaul, C | 1 |
| Resch, S | 1 |
| Raber, JM | 1 |
| Reichelt, D | 1 |
| Grüneberg-Oelker, U | 1 |
| Philipp, K | 1 |
| Stubbe-Dräger, B | 1 |
| Trbovich, M | 1 |
| Yang, H | 1 |
| Haanpää, M | 1 |
| McBride, WT | 1 |
| Docu Axelarad, A | 1 |
| Bosilkov, A | 1 |
| Chambers, C | 1 |
| Abdulahad, AK | 1 |
| Moon, JY | 1 |
| Lee, PB | 1 |
| Kim, YC | 1 |
| Lee, SC | 1 |
| Nahm, FS | 1 |
| Choi, E | 1 |
| Aitken, E | 1 |
| McColl, G | 1 |
| Kingsmore, D | 1 |
| Shibahara, H | 1 |
| Ando, A | 1 |
| Suzuki, S | 1 |
| Uematsu, N | 1 |
| Nishimura, D | 1 |
| Douchamps, F | 1 |
| Courtois, AC | 1 |
| Bruyère, PJ | 1 |
| Crielaard, JM | 1 |
| López Ramírez, E | 1 |
| Kiss, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| The Use of QUTENZA™ in Standard Clinical Practice: a Phase IV, Multicentre, European Non-interventional Study[NCT01737294] | 429 participants (Actual) | Observational | 2012-02-29 | Completed | |||
| Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)[NCT05162027] | Phase 2 | 5 participants (Actual) | Interventional | 2022-04-01 | Terminated (stopped due to Low enrollment rate) | ||
| Erenumab as a Therapeutic Approach for the Management of Trigeminal Neuropathic Pain (TNP)[NCT05142228] | Phase 2 | 5 participants (Actual) | Interventional | 2022-04-01 | Terminated (stopped due to Low enrollment rate) | ||
| EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.[NCT05025787] | Phase 2 | 77 participants (Anticipated) | Interventional | 2021-10-25 | Recruiting | ||
| Cryoneurolysis Outcome on Pain Experience (COPE) in Patients With Low-back Pain - a Single-blinded Randomized Controlled Trial[NCT04786145] | 120 participants (Anticipated) | Interventional | 2020-02-15 | Active, not recruiting | |||
| Gabapentin Versus Transdermal Fentanyl Matrix (TDF) for Chronic Neuropathic Pain (of Radicular Origin): A Multicenter Randomized, Parallel Group, Rater Blinded, Non-inferiority Trial[NCT01127100] | Phase 4 | 108 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Painful HIV-Associated Distal Symmetrical Polyneuropathy[NCT00064623] | Phase 3 | 300 participants | Interventional | 2003-08-31 | Completed | ||
| Preventive Application Of Lidocaine Patch In Adjunction To Intravenous Morphine Analgesia For Management Of Post-Thoracotomy Pain: Results Of A Randomized, Double Blind, Placebo Controlled Study[NCT02751619] | 90 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| Efficacy and Safety of 0.625% and 1.25% Capsaicin Patch in the Management of Peripheral Neuropathic Pain ; Early Phase II, Multi-center, Randomized, and Semi-double Blind Controlled Clinical Trial[NCT02228928] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| A Randonimised Trial Comparing Interrupted to Continuous Suturing Techniques in Radiocephalic Fistulae[NCT01704313] | 70 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for oxybutynin and Neuralgia
| Article | Year |
|---|---|
Capsaicin 179-mg cutaneous patch in the treatment of post-surgical neuropathic pain: a scoping review of current evidence and place in therapy.
Topics: Adult; Capsaicin; Diabetic Neuropathies; Humans; Neuralgia; Neuralgia, Postherpetic; Pain, Postopera | 2021 |
Utility of lidocaine as a topical analgesic and improvements in patch delivery systems.
Topics: Administration, Cutaneous; Analgesics; Humans; Lidocaine; Neuralgia; Transdermal Patch | 2020 |
Capsaicin 8% dermal patch in clinical practice: an expert opinion.
Topics: Administration, Topical; Analgesics; Capsaicin; Cost-Benefit Analysis; Expert Testimony; Humans; Neu | 2020 |
Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis.
Topics: Administration, Oral; Analgesics; Capsaicin; Diabetic Neuropathies; Humans; Neuralgia; Transdermal P | 2017 |
Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain.
Topics: Administration, Cutaneous; Analgesics; Capsaicin; HIV Infections; Humans; Neuralgia; Neuralgia, Post | 2018 |
Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain.
Topics: Adolescent; Adult; Capsaicin; Child; Child, Preschool; Female; Germany; Humans; Male; Middle Aged; N | 2013 |
Efficacy of Qutenza® (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database.
Topics: Aged; Aged, 80 and over; Capsaicin; Clinical Trials as Topic; Databases, Factual; Double-Blind Metho | 2013 |
[Localized neuropathic pain--5% lidocaine medicated patch as a first-line treatment and as add-on therapy: literature review and personal experience].
Topics: Adult; Aged; Algorithms; Anesthetics, Local; Female; Humans; Lidocaine; Male; Middle Aged; Neuralgia | 2014 |
12 trials available for oxybutynin and Neuralgia
| Article | Year |
|---|---|
Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study.
Topics: Adult; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; Neuralgia; Pain Management; Pain Me | 2017 |
High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience.
Topics: Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Capsaicin; Dose-Response Relationship, Drug; | 2017 |
Capsaicin 8% Patch Repeat Treatment in Nondiabetic Peripheral Neuropathic Pain: A 52-Week, Open-Label, Single-Arm, Safety Study.
Topics: Aged; Analgesics, Non-Narcotic; Capsaicin; Female; Humans; Hyperalgesia; Male; Middle Aged; Neuralgi | 2017 |
Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial.
Topics: Administration, Cutaneous; Adult; Analgesics; Double-Blind Method; Female; Fentanyl; Gabapentin; Hum | 2019 |
NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study.
Topics: Adult; Capsaicin; Double-Blind Method; Endpoint Determination; Female; HIV Infections; Humans; Kapla | 2014 |
Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study.
Topics: Administration, Cutaneous; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; Neuralgia; Pain | 2013 |
A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia.
Topics: Aged; Aged, 80 and over; Capsaicin; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Ma | 2013 |
Lidocaine 5 % patches as an effective short-term co-analgesic in cancer pain. Preliminary results.
Topics: Anesthetics, Local; Breast Neoplasms; Cicatrix; Female; Follow-Up Studies; Humans; Lidocaine; Male; | 2013 |
Tolerability of the capsaicin 8% patch following pretreatment with lidocaine or tramadol in patients with peripheral neuropathic pain: a multicentre, randomized, assessor-blinded study.
Topics: Adult; Aged; Analgesics, Opioid; Anesthetics, Local; Capsaicin; Female; Humans; Lidocaine; Male; Mid | 2014 |
Capsaicin 8 % as a cutaneous patch (Qutenza™): analgesic effect on patients with peripheral neuropathic pain.
Topics: Adult; Aged; Capsaicin; Female; Humans; Male; Middle Aged; Neuralgia; Pain Measurement; Sensory Syst | 2015 |
Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Capsaicin; Female; Humans; Male; M | 2016 |
Efficacy and Safety of 0.625% and 1.25% Capsaicin Patch in Peripheral Neuropathic Pain: Multi-Center, Randomized, and Semi-Double Blind Controlled Study.
Topics: Capsaicin; Double-Blind Method; Humans; Neuralgia; Pain Management; Pain Measurement; Transdermal Pa | 2017 |
25 other studies available for oxybutynin and Neuralgia
| Article | Year |
|---|---|
Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report.
Topics: Adult; Analgesics, Non-Narcotic; Carbamazepine; Dantrolene; Dizziness; Drug Interactions; Drug Thera | 2005 |
Capsaicin 8% Dermal Patch for Neuropathic Pain in a Pain Unit.
Topics: Capsaicin; Humans; Neuralgia; Quality of Life; Retrospective Studies; Transdermal Patch | 2022 |
Capsaicin 8% for Peripheral Neuropathic Pain Treatment: A Retrospective Cohort Study.
Topics: Capsaicin; Humans; Neuralgia; Quality of Life; Retrospective Studies; Transdermal Patch | 2022 |
Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment.
Topics: Analgesics; Analgesics, Opioid; Humans; Lidocaine; Neoplasms; Neuralgia; Pain Measurement; Prospecti | 2023 |
Using transdermal patches to treat neuropathic pain.
Topics: Anesthetics, Local; Capsaicin; Humans; Lidocaine; Neuralgia; Patient Education as Topic; Transdermal | 2020 |
Peripheral Neuropathy Associated with Hypereosinophilic Syndrome: A Clinical Therapeutic Success with Capsaicin 8% Patch.
Topics: Capsaicin; Humans; Hypereosinophilic Syndrome; Male; Middle Aged; Neuralgia; Pain Management; Periph | 2020 |
8% Capsaicin Patch in Treatment of Peripheral Neuropathic Pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Capsaicin; Child; Chronic Pain; Female; Humans; Male; Mi | 2020 |
In-Silico Validation and Fabrication of Matrix Diffusion-Based Polymeric Transdermal Patches for Repurposing Gabapentin Hydrochloride in Neuropathic Pain.
Topics: Analgesics; Computer Simulation; Diabetic Neuropathies; Drug Repositioning; Gabapentin; Humans; Mole | 2021 |
Post Laparoscopy Neuropathic Pain Treated by Capsaicin 8% Dermal Patch.
Topics: Capsaicin; Female; Humans; Laparoscopy; Middle Aged; Neuralgia; Transdermal Patch | 2021 |
Progressive Response to Repeat Application of Capsaicin 179 mg (8% w/w) Cutaneous Patch in Peripheral Neuropathic Pain: Comprehensive New Analysis and Clinical Implications.
Topics: Capsaicin; Humans; Neuralgia; Prospective Studies; Quality of Life; Transdermal Patch; Treatment Out | 2021 |
Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Capsaicin; Denmark; Female; Health Status; H | 2018 |
Efficacy Analysis of Capsaicin 8% Patch in Neuropathic Peripheral Pain Treatment.
Topics: Administration, Cutaneous; Aged; Capsaicin; Female; Humans; Male; Middle Aged; Neuralgia; Neuralgia, | 2018 |
Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy.
Topics: Aged; Analgesics; Anesthetics, Local; Drug Evaluation; Drug Resistance; Drug Therapy, Combination; E | 2018 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Topics: Activities of Daily Living; Adult; Aged; Analgesics; Capsaicin; Female; Humans; Male; Middle Aged; N | 2019 |
Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Analgesics, Opioid; Buprenorphine; CD4-CD8 Ratio; Female; | 2013 |
The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis.
Topics: Capsaicin; Failed Back Surgery Syndrome; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neura | 2013 |
Qutenza patch--our early experience.
Topics: Activities of Daily Living; Analgesics; Capsaicin; Chronic Pain; Humans; Neuralgia; Pain Measurement | 2013 |
Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary?
Topics: Analgesics; Analgesics, Opioid; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Capsaic | 2014 |
Application of the capsaicin 8% cutaneous patch in neuropathic pain of the head and face: A case series.
Topics: Aged; Capsaicin; Face; Female; Head; Humans; Male; Middle Aged; Neuralgia; Sensory System Agents; Tr | 2015 |
Capsaicin 8% Patch for Central and Peripheral Neuropathic Pain of Persons with Incomplete Spinal Cord Injury: Two Case Reports.
Topics: Adult; Aged; Capsaicin; Humans; Hyperalgesia; Male; Neuralgia; Pain Measurement; Sensory System Agen | 2015 |
The Role of Qutenza® (Topical Capsaicin 8%) in Treating Neuropathic Pain from Critical Ischemia in Patients with End-Stage Renal Disease: An Observational Cohort Study.
Topics: Administration, Topical; Adult; Aged; Capsaicin; Cohort Studies; Female; Humans; Ischemia; Kidney Fa | 2017 |
[Oxycodone and pregabalin using transdermal fentanyl patch provided relief of symptoms for postherpetic neuropathic pain in a patient with non-small cell lung cancer].
Topics: Aged; Analgesics, Opioid; Carcinoma, Non-Small-Cell Lung; Fentanyl; gamma-Aminobutyric Acid; Humans; | 2011 |
Supraclavicular nerve entrapment syndrome.
Topics: Analgesics; Antirheumatic Agents; Brachial Plexus; Clavicle; Humans; Lidocaine; Male; Middle Aged; N | 2012 |
Treatment of acute and chronic focal neuropathic pain in cancer patients with lidocaine 5 % patches. A radiation and oncology department experience.
Topics: Acute Pain; Aged; Aged, 80 and over; Anesthetics, Local; Chronic Pain; Female; Humans; Lidocaine; Ma | 2013 |
[Practical information about Qutenza patch: capsaicin "reloaded"].
Topics: Analgesics, Non-Narcotic; Capsaicin; Humans; Neuralgia; Transdermal Patch | 2012 |